Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis

Scandinavian Journal of Immunology

Volumn 45, Issue 2, 1997, Pages 132-139

  Eigler, A ^a   Greten, T F ^a   Sinha, B ^a   Haslberger, C ^a   Sullivan, G W ^b   Endres, S ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ADENOSINE DEAMINASE; DIPYRIDAMOLE; LIPOPOLYSACCHARIDE; ROLIPRAM; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; HUMAN; HUMAN CELL; LEUKOCYTE CULTURE; NORMAL HUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0031022361     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-377.x     Document Type: Article

References (38)

1. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993;269:1829-35.
2. Ellioti MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
3. Gadina M, Bertini R, Mengozzi M, Zandalasini M, Mantovani A, Ghezzi P. Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock. J Exp Med 1991;173:1305-10.
4. Semmler J, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Intern J Immunopharmacol 1993;15:409-13.
5. Sommer N, Löschmann PA, Northoff GH et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med 1995; 1:244-8.
6. Eisenhut T, Sinha B, Gröttrup-Wolfers E, Semmler J, Siess W, Endres S. Prostacyclin analogs suppress the synthesis of tumor necrosis factor-α in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology 1993;26:259-64.
7. Sinha B, Semmler J, Eisenhut T, Eigler A, Endres S. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol 1995;25:147-53.
8. Crutchley DJ, Conanan LB, Que BG. Effects of prostacyclin analogs on the synthesis of tissue factor, tumor necrosis factor-alpha and interleukin-1 beta in human monocytic THP-1 cells. J Pharmacol Exp Ther 1994;271:446-51.
9. 2 receptors. J Exp Med 1991;174:281-4.
10. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995;270:9558-63.
11. Marchant A, Bruyns C, Vandenabeele P et al. Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 1994;24: 1167-71.
12. Eigler A, Moeller J, Endres S. Exogenous and endogenous nitric oxide attenuates tumor necrosis factor synthesis in the murine macrophage cell line RAW 264.7. J Immunol 1995;154:4048-54.
13. Endres S, Ghorbani R, Kelley VE et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320:265-71.
14. Parmely MJ, Zhou WW, Edwards CK, Borcherding DR, Silverstein R, Morrison DC. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-α roduction and protect mice against endotoxin challenge. J Immunol 1993;151:389-6.
15. Firestein GS, Boyle D, Bullough DA et al. Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol 1994;152:853-9.
16. Bouma MG, Stad RK, van den Wildenberg FAJM, Buurman WA. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994;153:4159-68.
17. Cronstein BN, Levin RI, Belanoff J, Weissmann G, Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986;78:760-70.
18. 1 receptors and inhibited via adenosine A: receptors. J Immunol 1992;148:2201-6.
19. Sullivan GW, Luong LS, Carper HT, Barnes CR, Mandell GL. Methylxanthines with adenosine alter tumor necrosis factor α-primed neutrophil activation. Immunopharmacology 1995;31:19-29.
20. van der Meer JW, Endres S, Lonnemann G et al. Concentrations of immunoreactive human tumor necrosis factor a produced by human mononuclear cells in vitro. J Leukocyte Biol 1988;43:216-23.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-9.
22. Sullivan GW, Linden J, Hewlett EL, Carper HT, Hylton JB, Mandell GL. Adenosine and related compounds counteract tumor necrosis factor-alpha inhibition of neutrophil migration: implication of a novel cyclic AMP-independent action on the cell surface. J Immunol 1990;145:1537-44.
23. 2 receptors on rat Kupffer cells. Hepalology 1994;19:1445-52.
24. Prabhakar U, Brooks DP, Lipshutz D, Esser KM. Inhibition of LPS-induced TNFα production in human monocytes by adenosine (A2) receptor selective agonists. Int J Immunopharmacol 1995;17:221-4.
25. Thiel M, Chouker A. Acting via A2 receptors, adenosine inhibits the production of tumor necrosis factor-α of endotoxin-stimulated human polymorphonuclear leukocytes. J Lab Clin Med 1995;126:275-82.
26. Collis MG, Hourani SM. Adenosine receptor subtypes. Trends Pharmacol Sci 1993;14:360-6.
27. Taffet SM, Singhel KJ, Overholtzer JF, Shurtleff SA. Regulation of tumor necrosis factor expression in a macrophage-like cell line by lipopolysaccharide and cyclic AMP. Cell Immunol 1989; 120:291-300.
28. Tannenbaum CS, Hamilton TA. Lipopolysaccharide-induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J Immunol 1989;142:1274-80.
29. Prabhakar U, Lipshutz D, O'Leary Bartus J et al. Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharmacol 1994;16:805-16.
30. Turner CR, Andresen CJ, Smith WB, Watson JW. Effects of rolipram on responses to acute and chronic antigen exposure in monkeys. Amer J Respir Crit Care Med 1994;149:1153-9.
31. Derian CK, Santulli RJ, Rao PE, Solomon HF, Barrett JA. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J Immunol 1995;154:308-17.
32. Sullivan GW, Carper HT, Mandell GL. The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-α-primed neutrophil oxidative activity. Int J Immunopharmac 1995;17:793-803.
33. 2-adenosine antagonist in vitro and in vivo. FEBS Lett 1993;323:141-4.
34. Barnes CR, Mandell GL, Carper HT, Luong S, Sullivan GW. Adenosine modulation of tumor necrosis factor-α-induced neutrophil activation. Biochem Pharmacol 1995;50:1851-7.
35. Möser GH, Schrader J, Deussen A. Turnover of adenosine in plasma of human and dog blood. Am J Physiol 1989;256:C799-C806.
36. Ontyd J, Schrader J. Measurement of adenosine, inosine, and hypoxanthine in human plasma. J Chromatogr 1984;307:404-9.
37. Bardenheuer H, Forst H, Haller M, Peter K. Influence of improved tissue oxygenation on plasma adenosine (ADO) in septic patients. (Abstract). Int Care Med 1990;165:536.
38. Cronstein BN. A novel approach to the development of antiinflammatory agents: adenosine release at inflamed sites. J Invest Med 1995;43:50-7.